How much did Gilead Sciences achieve in EBIT for the current year?
In the current year, Gilead Sciences has achieved an EBIT of 10.43 B USD.
In 2024, Gilead Sciences's EBIT was 10.43 B USD, a 11.65% increase from the 9.34 B USD EBIT recorded in the previous year.
YEAR | EBIT (undefined USD) |
---|---|
2029e | - |
2028e | 13.48 |
2027e | 13 |
2026e | 12.61 |
2025e | 12.06 |
2024e | 10.43 |
2023 | 9.34 |
2022 | 10.03 |
2021 | 9.92 |
2020 | 4.07 |
2019 | 4.46 |
2018 | 8.37 |
2017 | 14.39 |
2016 | 18.47 |
2015 | 22.19 |
2014 | 15.38 |
2013 | 4.59 |
2012 | 4.01 |
2011 | 3.86 |
2010 | 4.14 |
2009 | 3.59 |
2008 | 2.69 |
2007 | 2.17 |
2006 | 1.64 |
2005 | 1.11 |
2004 | 0.63 |
In the annual report of the Gilead Sciences share (US3755581036, 885823, GILD), it breaks down its revenues into 1 segments: 1. innovative Medicines. The Gilead Sciences stock (WKN: 885823, ISIN: US3755581036, Ticker Symbol: GILD) is a leading investment for investors interested in participating in the Health Care sector.
Gilead Sciences's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
A yearly comparison of Gilead Sciences's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Gilead Sciences's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Fluctuations in Gilead Sciences’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
In the current year, Gilead Sciences has achieved an EBIT of 10.43 B USD.
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Gilead Sciences.
The EBIT of Gilead Sciences has increased by 11.653% increased compared to the previous year.
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
The EBIT of Gilead Sciences is listed in the income statement.
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
Over the past 12 months, Gilead Sciences paid a dividend of 3 USD . This corresponds to a dividend yield of about 4.47 %. For the coming 12 months, Gilead Sciences is expected to pay a dividend of 0.63 USD.
The current dividend yield of Gilead Sciences is 4.47 %.
Gilead Sciences pays a quarterly dividend. This is distributed in the months of July, October, January, April.
Gilead Sciences paid dividends every year for the past 15 years.
For the upcoming 12 months, dividends amounting to 0.63 USD are expected. This corresponds to a dividend yield of 0.94 %.
Gilead Sciences is assigned to the 'Health' sector.
To receive the latest dividend of Gilead Sciences from 3/28/2024 amounting to 0.77 USD, you needed to have the stock in your portfolio before the ex-date on 3/14/2024.
The last dividend was paid out on 3/28/2024.
In the year 2023, Gilead Sciences distributed 2.92 USD as dividends.
The dividends of Gilead Sciences are distributed in USD.
The Gilead Sciences stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank
Our stock analysis for Gilead Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gilead Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.